Cellares Corporation, a US-based life sciences technology company, announced on May 5, 2021 that it has raised $82 million in a Series B round to accelerate the development of its Cell Shuttle, a factory-in-a-box that allows for the automation of the process of creating highly individualized cell therapies, including chimeric antigen receptor (CAR)-T therapies. The Cell Shuttle is equipped with hardware, software, robotics, and consumables, making it capable of producing 10 patient doses simultaneously. Source: Biopharm International 5/5/2021